Acute Coronary Syndromes and SARS-CoV-2 Infection: Results From an Observational Multicenter Registry During the Second Pandemic Spread in Lombardy.
COVID-19
STEMI (myocardial infarction)
acute coronary syndrome
coronary angiography
hub
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
04
2022
accepted:
24
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
COVID-19 had an adverse impact on the management and outcome of acute coronary syndromes (ACS), but most available data refer to March-April 2020. This study aims to investigate the clinical characteristics, time of treatment, and clinical outcome of patients at hospitals serving as macro-hubs during the second pandemic wave of SARS-CoV-2 (November 2020-January 2021). Nine out of thirteen "macro-hubs" agreed to participate in the registry with a total of 941 patients included. The median age was 67 years (IQR 58-77) and ST-elevation myocardial infarction (STEMI) was the clinical presentation in 54% of cases. Almost all patients (97%) underwent coronary angiography, with more than 60% of patients transported to a macro-hub by the Emergency Medical Service (EMS). In the whole population of STEMI patients, the median time from symptom onset to First Medical Contact (FMC) was 64 min (IQR 30-180). The median time from FMC to CathLab was 69 min (IQR 39-105). A total of 59 patients (6.3%) presented a concomitant confirmed SARS-CoV-2 infection, and pneumonia was present in 42.4% of these cases. No significant differences were found between STEMI patients with and without SARS-CoV-2 infection in treatment time intervals. Patients with concomitant SARS-CoV-2 infection had a significantly higher in-hospital mortality compared to those without (16.9% vs. 3.6%, During the second wave of SARS-CoV-2 infection, almost all patients with ACS received coronary angiography for STEMI with an acceptable time delay. Patients with concomitant infection presented a lower in-hospital survival with no difference in post-discharge mortality; infection by itself was not an independent predictor of mortality but pneumonia was.
Sections du résumé
Background
UNASSIGNED
COVID-19 had an adverse impact on the management and outcome of acute coronary syndromes (ACS), but most available data refer to March-April 2020.
Aim
UNASSIGNED
This study aims to investigate the clinical characteristics, time of treatment, and clinical outcome of patients at hospitals serving as macro-hubs during the second pandemic wave of SARS-CoV-2 (November 2020-January 2021).
Methods and Results
UNASSIGNED
Nine out of thirteen "macro-hubs" agreed to participate in the registry with a total of 941 patients included. The median age was 67 years (IQR 58-77) and ST-elevation myocardial infarction (STEMI) was the clinical presentation in 54% of cases. Almost all patients (97%) underwent coronary angiography, with more than 60% of patients transported to a macro-hub by the Emergency Medical Service (EMS). In the whole population of STEMI patients, the median time from symptom onset to First Medical Contact (FMC) was 64 min (IQR 30-180). The median time from FMC to CathLab was 69 min (IQR 39-105). A total of 59 patients (6.3%) presented a concomitant confirmed SARS-CoV-2 infection, and pneumonia was present in 42.4% of these cases. No significant differences were found between STEMI patients with and without SARS-CoV-2 infection in treatment time intervals. Patients with concomitant SARS-CoV-2 infection had a significantly higher in-hospital mortality compared to those without (16.9% vs. 3.6%,
Conclusion
UNASSIGNED
During the second wave of SARS-CoV-2 infection, almost all patients with ACS received coronary angiography for STEMI with an acceptable time delay. Patients with concomitant infection presented a lower in-hospital survival with no difference in post-discharge mortality; infection by itself was not an independent predictor of mortality but pneumonia was.
Identifiants
pubmed: 35783857
doi: 10.3389/fcvm.2022.912815
pmc: PMC9243433
doi:
Types de publication
Journal Article
Langues
eng
Pagination
912815Informations de copyright
Copyright © 2022 Ferlini, Castini, Ferrante, Marenzi, Montorfano, Savonitto, D’Urbano, Lettieri, Cuccia, Marino, Visconti and Carugo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Coll Cardiol. 2021 May 25;77(20):2466-2476
pubmed: 34016259
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Front Cardiovasc Med. 2021 Jan 28;7:593496
pubmed: 33585577
Eur Heart J. 2020 May 14;41(19):1839-1851
pubmed: 32405641
J Am Coll Cardiol. 2021 Apr 27;77(16):1994-2003
pubmed: 33888249
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Int J Cardiol. 2021 Jan 15;323:288-291
pubmed: 32858138
Int J Cardiol. 2020 Aug 1;312:24-26
pubmed: 32339543
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Expert Rev Cardiovasc Ther. 2020 Aug;18(8):531-539
pubmed: 32672482
Lancet. 2022 Apr 16;399(10334):1513-1536
pubmed: 35279232
J Am Coll Cardiol. 2020 Nov 17;76(20):2321-2330
pubmed: 33183506
Rev Esp Cardiol. 2020 Dec;73(12):985-993
pubmed: 32963419
N Engl J Med. 2020 Jul 30;383(5):496-498
pubmed: 32348640
Eur J Intern Med. 2022 May;99:109-111
pubmed: 35131161
J Am Coll Cardiol. 2021 Jan 19;77(2):159-169
pubmed: 33446309
Heart. 2020 Oct;106(20):1609-1616
pubmed: 32878920
Int J Cardiol Heart Vasc. 2020 Dec;31:100662
pubmed: 33173807
BMJ. 2006 Nov 25;333(7578):1091
pubmed: 17032691
Eur Heart J. 2022 Mar 14;43(11):1059-1103
pubmed: 34791154
Eur Heart J. 2020 Jun 7;41(22):2083-2088
pubmed: 32412631
Circ Cardiovasc Qual Outcomes. 2020 Apr;13(4):e006631
pubmed: 32182131
Kardiol Pol. 2020 Dec 23;78(12):1227-1234
pubmed: 32955819